Trial Profile

Inhaled ZYESAMI for the Treatment of Severe COVID-19

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aviptadil (Primary)
Indications COVID-19 respiratory infection; Respiratory insufficiency
Focus Therapeutic Use
Acronyms AVICOVID-2
Sponsors APR Applied Pharma Research; NeuroRX; NRx Pharmaceuticals

Most Recent Events

02 Feb 2023 Status changed from recruiting to discontinued.
05 Sep 2021 Planned End Date changed from 1 Sep 2021 to 31 Dec 2021.
05 Sep 2021 Planned primary completion date changed from 15 Aug 2021 to 15 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com